CN105998046A - 用于治疗造血性癌症和增殖性病症的固定药物比例 - Google Patents

用于治疗造血性癌症和增殖性病症的固定药物比例 Download PDF

Info

Publication number
CN105998046A
CN105998046A CN201610324431.2A CN201610324431A CN105998046A CN 105998046 A CN105998046 A CN 105998046A CN 201610324431 A CN201610324431 A CN 201610324431A CN 105998046 A CN105998046 A CN 105998046A
Authority
CN
China
Prior art keywords
cytarabine
daunorubicin
dose
cpx
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610324431.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·路易
C·斯温森
L·梅尔
A·雅诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105998046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Priority claimed from CN200880009406A external-priority patent/CN101657098A/zh
Publication of CN105998046A publication Critical patent/CN105998046A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN201610324431.2A 2007-02-16 2008-02-15 用于治疗造血性癌症和增殖性病症的固定药物比例 Pending CN105998046A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US60/901,772 2007-02-16
US96519607P 2007-08-17 2007-08-17
US60/965,196 2007-08-17
CN200880009406A CN101657098A (zh) 2007-02-16 2008-02-15 用于治疗造血性癌症和增殖性病症的固定药物比例

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880009406A Division CN101657098A (zh) 2007-02-16 2008-02-15 用于治疗造血性癌症和增殖性病症的固定药物比例

Publications (1)

Publication Number Publication Date
CN105998046A true CN105998046A (zh) 2016-10-12

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610324431.2A Pending CN105998046A (zh) 2007-02-16 2008-02-15 用于治疗造血性癌症和增殖性病症的固定药物比例

Country Status (20)

Country Link
US (2) US8092828B2 (enExample)
EP (3) EP3300601B1 (enExample)
JP (1) JP5314600B2 (enExample)
KR (2) KR20150038752A (enExample)
CN (1) CN105998046A (enExample)
AU (1) AU2008216083B2 (enExample)
CA (1) CA2678332C (enExample)
CY (1) CY1119631T1 (enExample)
DK (2) DK2120568T3 (enExample)
ES (2) ES2650167T3 (enExample)
FR (1) FR22C1034I2 (enExample)
HR (1) HRP20220428T3 (enExample)
HU (2) HUE058334T2 (enExample)
LU (1) LUC00271I2 (enExample)
NL (1) NL301185I2 (enExample)
NO (2) NO2120568T3 (enExample)
PL (2) PL2120568T3 (enExample)
PT (2) PT3300601T (enExample)
SI (1) SI3300601T1 (enExample)
WO (1) WO2008101214A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN113164502A (zh) * 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
CN104114156A (zh) * 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6976941B2 (ja) * 2015-11-11 2021-12-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP7580378B2 (ja) 2018-12-04 2024-11-11 デル－ヤン ティエン， 抗がん剤の送達のためのステレオコンプレックス
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102359A1 (en) * 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
KR20050072790A (ko) * 2002-11-06 2005-07-12 셀진 코포레이션 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102359A1 (en) * 2004-04-22 2005-11-03 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN113164502A (zh) * 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗

Also Published As

Publication number Publication date
NO2022027I1 (no) 2022-06-30
DK3300601T3 (da) 2022-03-21
ES2650167T3 (es) 2018-01-17
FR22C1034I2 (fr) 2023-06-30
HUE058334T2 (hu) 2022-07-28
JP5314600B2 (ja) 2013-10-16
US20100303895A1 (en) 2010-12-02
HUS2200032I1 (hu) 2022-07-28
EP4046640A1 (en) 2022-08-24
WO2008101214A2 (en) 2008-08-21
FR22C1034I1 (fr) 2022-09-09
AU2008216083A1 (en) 2008-08-21
PT2120568T (pt) 2017-12-04
CA2678332C (en) 2015-06-02
KR20150038752A (ko) 2015-04-08
EP2120568A2 (en) 2009-11-25
EP3300601A1 (en) 2018-04-04
WO2008101214A3 (en) 2008-11-20
EP3300601B1 (en) 2022-01-12
DK2120568T3 (en) 2017-12-11
EP2120568A4 (en) 2010-04-21
NL301185I2 (nl) 2022-07-21
AU2008216083A2 (en) 2009-09-24
SI3300601T1 (sl) 2022-05-31
PL3300601T3 (pl) 2022-05-02
KR20100014441A (ko) 2010-02-10
CY1119631T1 (el) 2018-04-04
PL2120568T3 (pl) 2018-03-30
HK1253378A1 (en) 2019-06-14
AU2008216083B2 (en) 2014-02-06
US8092828B2 (en) 2012-01-10
US20080199515A1 (en) 2008-08-21
HRP20220428T3 (hr) 2022-05-27
PT3300601T (pt) 2022-04-21
CA2678332A1 (en) 2008-08-21
NO2120568T3 (enExample) 2018-04-14
JP2010519224A (ja) 2010-06-03
LUC00271I2 (enExample) 2025-04-25
EP2120568B1 (en) 2017-11-15
ES2909903T3 (es) 2022-05-10

Similar Documents

Publication Publication Date Title
CN105998046A (zh) 用于治疗造血性癌症和增殖性病症的固定药物比例
EP1744764A1 (en) Liposomal formulations of anthracycline agents and cytidine analogs
Eckardt et al. A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon
KR20070089693A (ko) 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
CN101657098A (zh) 用于治疗造血性癌症和增殖性病症的固定药物比例
EP3891207B1 (en) Stereocomplexes for the delivery of anti-cancer agents
US20090074848A1 (en) Combination formulations of cytidine analogs and platinum agents
US7204996B2 (en) Method of cancer treatment
CN112601527B (zh) 用于有效预防和治疗的选择性抗癌剂
Bieker et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia
HK40079853A (en) Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
HK1253378B (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
HK1137294B (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
HK1137294A (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
AU2021249949B2 (en) Antitumor agent
Morgan Jr et al. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer—long-term follow-up
CN120225196A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
Lerchenmüller et al. Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia
EP3664809A1 (en) Liposomal taxanes for treatment of sclc
CN101330917A (zh) 固定比率的联合用药治疗实体瘤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161012

RJ01 Rejection of invention patent application after publication